How do myosin inhibitors perform in different HCM phenotypes?

Cardiac myosin inhibitors have been developed as a targeted therapeutic option for modulating sarcomere function. While in clinical trials in obstructive hypertrophic cardiomyopathy they brought about a greater improvement in exercise tolerance and symptoms than placebo and beta-blockers, in a recent Phase III trial in non-obstructive phenotypes there were no significant differences in the placebo comparison.